How is the Daratumumab Or Darzalex Market Poised for Growth: Trends and Opportunities Through 2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the daratumumab or darzalex market?
Over the past few years, the market size for daratumumab or daralex has witnessed substantial growth. The market is estimated to expand from a worth of $5,093.04 million in 2024 to a value of $5,618.30 million in 2025, displaying a compound annual growth rate (CAGR) of 10.3%. The progress seen in the historic period is due to factors such as the implementation of diverse research methods, the expansion of feasible biomanufacturing practices, the rise in the utilization of monoclonal antibodies, the increased number of strategic endeavors, and the heightened production of mAbs.
What will be the daratumumab or darzalex market size in the future?
Expectations are high for the daratumumab or darzalex market to experience a notable surge in growth soon. It is predicted to rise to a valuation of $8,189.36 million in 2029, recording a compound annual growth rate (CAGR) of 10.0%. Multiple factors will contribute to this growth during the forecast period, such as increased clinical evidence, accelerating adoption in earlier treatment stages, a boost in biologics demand, growing levels of patient awareness, a higher incidence rate of blood cancer, and the mounting prevalence of chronic diseases. The forecast period will also observe major trends like technological evolution, product and service offerings, new product introductions, collaborations, partnerships, mergers and acquisitions, and developments in radiation technologies.
Get your daratumumab or darzalex market report here!
https://www.thebusinessresearchcompany.com/report/daratumumab-or-darzalex-global-market-report
What main drivers are fueling expansion in the daratumumab or darzalex market?
The escalation in bone marrow cancer occurrence is anticipated to boost the daratumumab or darzalex market’s expansion. Bone marrow cancer includes malignancies like multiple myeloma and leukemia that initiate in the bone marrow and disrupt normal bodily functions due to irregular blood cell production. This surge in bone marrow cancer cases can be ascribed to aging society, improved detection techniques, environmental impacts, lifestyle selections, and genetic predispositions. Daratumumab (Darzalex) plays a crucial role in treating multiple myeloma, a form of bone marrow cancer, as it targets and eradicates the abnormal plasma cells in the marrow. The American Cancer Society projected in January 2024 that there would be 89,190 lymphoma cases, a rise from 89,010 in 2022, and 35,780 cases of myeloma, an increase from 34,470 in 2022. Hence, the escalation in bone marrow cancer occurrence is the key driver of the daratumumab or darzalex market’s development. The heightened acceptance of biologics and specific therapies is projected to fuel the daratumumab or darzalex market’s development. Specific therapies are a kind of medical treatment that employs drugs or other substances to accurately identify and combat molecules essential for the progression and survival of cancer or other diseases. Chronic ailments prevalence and precision medicine advancements are escalating the acceptance of biologics and targeted therapies as these advancements enable more personalized and effective treatments. Daratumumab is used in targeted therapies due to its specific action on CD38, a protein abundantly present on the surface of malignant plasma cells in multiple myeloma. The Advanced Therapy Treatment Centers (ATTC) revealed in December 2023 that annual investments in advanced therapies increased by 31% in 2022, with the UK now constituting 14% of all worldwide commercial ATMP clinical trials. Thus, the heightened acceptance of biologics and specific therapies is propelling the daratumumab or darzalex market’s expansion.
What key areas define the segmentation of the global daratumumab or darzalex market?
The daratumumab or darzalexmarket covered in this report is segmented –
1) By Drug Type: 100Mg Injection; 400Mg Injection
2) By Distribution Channel: Pharmacies; Hospital; Other Distribution Channels
3) By Application: Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma; Diffuse Large B Cell Lymphoma; Other Applications
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19896&type=smp
Who are the dominant players expanding their reach in the daratumumab or darzalex market?
Major companies operating in the daratumumab or darzalex market include Genmab A/S, Janssen Biotech Inc.
How are evolving market trends shaping daratumumab or darzalex Strategies?
One of the primary trends prevailing in the Daratumumab or Darzalex market sees a shift towards early intervention oncology treatments like combination therapies to bolster effectiveness in treating multiple myeloma and various types of cancer. Combination therapies utilize more than one therapeutic agent, each with their unique mode of action, often in accordance to enhance effectiveness, curb resistance, and enhance patient outcomes, potentially minimizing adverse effects when compared to monotherapy. In July 2024, a leading U.S. pharmaceutical company, Johnson & Johnson, earned U.S. FDA approval for the use of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd), for induction and consolidation treatments in patients recently diagnosed with multiple myeloma and qualified for autologous stem cell transplant (ASCT). This approval gives rise to a new therapy option at the point of initial diagnosis, serving to improve patient outcomes.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19896
Which regions are emerging as leaders in the daratumumab or darzalex market?
North America was the largest region in the daratumumab or darzalex market in 2024. The regions covered in the daratumumab or darzalex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Antibody Contract Manufacturing Global Market Report 2025
Next-Generation Antibody Therapeutics Global Market Report 2025
Antibody Drug Conjugates Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
